Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer

GIORGIO SCAGLIOTTI, a RAMASWAMY GOVINDANb

aUniversity of Turin, Department of Clinical & Biological Sciences, Orbassano (Turin), Italy; bWashington University School of Medicine, St. Louis, Missouri, USA

Key Words. Antiangiogenesis • Multitargeted agents • Tyrosine kinase inhibitor • Non-small cell lung cancer

Disclosures: Giorgio Scagliotti: None; Ramaswamy Govindan: Consultant/advisory role: AstraZeneca, Boehringer Ingelheim, Genentech, Lilly.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.

ABSTRACT

It has been >35 years since the link between angiogenesis and the growth of tumors was first reported. Targeting angiogenesis became feasible with the availability of bevacizumab, an anti–vascular endothelial growth factor monoclonal antibody. Initial studies revealed that the combination of bevacizumab and chemotherapy led to longer overall survival times than with chemotherapy alone in patients with advanced colorectal cancer. Since then, drug development strategies have added small molecule tyrosine kinase inhibitors to the panel of antiangiogenic agents under evaluation; data from numerous trials are now available. The challenge now is to identify the optimal antiangiogenic agent for specific patient groups and to understand not only the mechanistic differences between agents, but also the variability in their antitumor activity across different tumor types and their differing side-effect profiles. As in other solid tumors, angiogenesis contributes to the development of non-small cell lung cancer (NSCLC), and this review summarizes the role of angiogenesis in this disease. We review the current developmental status of antiangiogenic tyrosine kinase inhibitors (including vandetanib, sunitinib, axitinib, sorafenib, vatalanib, and pazopanib) in NSCLC and conclude by briefly discussing the need for optimal patient selection and potential future directions. The Oncologist 2010;15:436–446

INTRODUCTION

Angiogenesis is a complex process that is essential for the growth of tumors. Judah Folkman first suggested that tumor growth was dependent on angiogenesis in 1971, predicting that tumor size would be limited to 1–2 mm in the absence of angiogenesis and that tumor cells secrete a protein that stimulates angiogenesis [1, 2]. In order for angiogenesis to occur, several signaling pathways must be suppressed or activated [3]. Some of these signaling pathways, such as the vascular endothelial growth factor (VEGF) pathway and platelet-derived growth factor (PDGF) pathway, control the activity of blood vessel–associated cells, including endothelial cells and pericytes.

Whereas the primary stimulus for angiogenesis in the
tumor microenvironment is the hypoxia-driven activation of hypoxia-inducible factor-1α, and the subsequent activation of VEGF. Numerous other growth factors and protein products of oncogenes and tumor-suppressor genes are also involved (Table 1) [4]. As tumor-associated blood vessels develop, cytokine-rich plasma is exuded and provides a gradient along which new endothelial cells migrate and new capillary tubes form [5]. Under normal physiologic conditions, blood vessel maturation occurs when endothelial cells secrete PDGF, which in turn stimulates pericyte recruitment. However, tumor-associated vasculature fails to mature completely, typically as a result of the development of hypoxic regions in the tumor that stimulate a perpetual cycle of VEGF production, angiogenesis, and further tumor growth [6]. Because angiogenesis is a complex process mediated by many factors, there are potentially multiple signaling pathways involved that can be targeted by antitumor therapies (Fig. 1). While targeting one signaling pathway may be effective, targeting several interconnected signaling pathways may theoretically result in increased therapeutic benefit, particularly as the tumor may utilize alternative signaling pathways as “escape” mechanisms [7]. This concept is supported by data that suggest an additive effect on tumor response when both the VEGF and PDGF signaling pathways are inhibited [8–10]. Preclinical research has identified several targeted antiangiogenic agents, including monoclonal antibodies and tyrosine kinase inhibitors (TKIs). Monoclonal antibodies prevent receptor activation by binding directly to the ligand, whereas TKIs inhibit kinase activity by competing with ATP in the tyrosine kinase catalytic domain. This review describes the role of angiogenesis in non-small cell lung cancer (NSCLC) and summarizes some of the available data from studies of antiangiogenic agents.

Although multtargeted TKIs are the focus of this review, it is important to consider that numerous antiangiogenic/antivascular agents with alternative mechanisms of action are in preclinical/early clinical development. These include aflibercept, a recombinant fusion protein that binds all isoforms of VEGF, the combretastatins (e.g., CA-4-P), which are tubulin-binding, vascular-disrupting agents, and the bisphosphonates, which may reduce the incidence of bone metastases through antiangiogenic mechanisms.

**TUMOR ANGIOGENESIS**

VEGF is one of the most potent mediators of tumor angiogenesis. There are four homologues within the VEGF gene family: VEGF-A, VEGF-B, VEGF-C, and VEGF-D. VEGF-A is a key regulator of blood vessel development in adult tissues, whereas VEGF-B is implicated in embryonic angiogenesis. VEGF-C and VEGF-D are thought to be primarily involved in lymphatic angiogenesis. The VEGF ligands bind to three VEGF receptors (VEGFRs): VEGFR-1 (also known as Flt-1), VEGFR-2 (also known as KDR), and VEGFR-3 (also known as Flt-4). VEGFR-2 is the primary receptor involved in endothelial cell proliferation and migration [11].

Signaling pathways activated by PDGF are integral to the growth and survival of vascular smooth muscle cells and pericytes [12, 13]. There are three active forms of the PDGF protein: PDGF-AA, PDGF-BB, and PDGF-AB (two other forms that require proteolytic cleavage before activation can occur are PDGF-CC and PDGF-DD). These ligands bind with varying affinity to the two receptor subunits (PDGFRα and PDGFRβ), which subsequently dimerize to form PDGFRαα, PDGFRββ, or PDGFRαβ. PDGFR expression on pericytes is an essential requirement for the survival of tumor vasculature [14].

Other factors with pro-/antiangiogenic properties include epidermal growth factor (EGF), stem cell factor, fibroblast growth factor (FGF), colony-stimulating factor (CSF)-1, angiopoietin (Ang)-1/Tie-2, placental growth factor, endothelin (ET)-1 and ET-2, thrombospondin, angiostatin, endostatin, and lactate (Table 1). EGF has been linked to cell proliferation, apoptosis, angiogenesis, and metastatic spread in many human carcinomas, whereas overexpression of wild-type EGF receptor (EGFR) has also
been associated with increased angiogenesis and poor prognosis in NSCLC [15, 16].

Although angiogenesis is the primary mechanism by which tumors coopt a blood supply, other methods are also used. These methods include intussusceptive microvascular growth, vasculogenesis via the recruitment of bloodborne endothelial progenitor cells, glomeruloid angiogenesis, and vasculogenic mimicry [3, 7]. Angiogenesis, as measured using microvessel density (MVD), can be a predictor of poor survival in a variety of neoplasms, including NSCLC [17, 18]. Studies have also shown that levels of VEGF (and PDGF) correlate significantly with increased angiogenesis, poor prognosis, and lymph node metastasis in patients with NSCLC [8, 17–20]. Indeed, high levels of VEGF have been linked to shorter survival in patients with NSCLC who received the VEGFR and EGFR inhibitor van- detanib [21, 22]. Furthermore, an immunohistochemical study of NSCLC tumor specimens found that MVD was higher in samples from patients with advanced-stage than those with early-stage NSCLC, and it was also higher in patients with lymph node metastases than in those with no metastases [23]. This same study also hypothesized that high levels of the antiangiogenic factor thrombospondin-1 may delay disease progression [23].

STANDARDS OF CARE FOR THE SYSTEMIC TREATMENT OF ADVANCED NSCLC
Approximately 219,000 new lung cancer cases and 160,000 deaths were estimated to have occurred in the U.S. in 2009 [24]. Most patients with lung cancer present with advanced disease and, globally, platinum-based doublet chemotherapy remains the standard of care for patients with a good performance status [25]. Although numerous systemic chemotherapy doublets and triplets have been studied, they produce similar outcomes. However, promising data have been reported with the folate antimetabolite, pemetrexed (Alimta®; Eli Lilly and Company, Indianapolis, Indiana), in both a first-line setting [26] and as maintenance therapy [27]. First-line cisplatin plus pemetrexed was noninferior to cisplatin plus gemcitabine, although a significant survival advantage with cisplatin plus pemetrexed was observed in patients with adenocarcinoma or large-cell carcinoma [26].

Based on maintenance data revealing that pemetrexed doubled the time to disease progression, compared with placebo (4.04 months versus 1.97 months), in July 2009 pemetrexed was approved in the U.S. and European Union as maintenance therapy in NSCLC patients with nonsquamous histology [27].

Clinical research efforts with targeted agents have endeavored to improve survival beyond that provided by chemotherapy. Two pivotal phase III trials provide the foundation for using targeted antiangiogenic agents in NSCLC. The Eastern Cooperative Oncology Group (ECOG) 4599 trial randomized patients with advanced nonsquamous NSCLC to receive paclitaxel and carboplatin with or without the anti-VEGF monoclonal antibody bevacizumab (Avastin®; Genentech, San Francisco, CA), or placebo. That study reported a median overall survival (OS) time of 12.3 months with the addition of bevacizumab to chemotherapy, and only 10.3 months with chemotherapy alone [28]. The study established that the VEGF pathway is a valid target for therapy. Subsequently, a second phase III European trial, AVAstin in Lung (AVAiL), assessed bevacizumab (7.5 mg/kg and 15 mg/kg) in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent NSCLC. That study demonstrated a higher objective response rate (ORR) and longer progression-free survival (PFS) time with both doses of bevacizumab; the ORRs were 20.1 months (placebo), 34.1 months (7.5 mg/kg), and 30.4 months (15 mg/kg). The median PFS time was significant for the 7.5 mg/kg dose level (6.5 months versus 6.1 months; \( p = .003 \)). No statistically significant improvement in OS was observed. The reason for a lack of survival benefit is unclear, with proposed reasons including poststudy treatment, a potentially smaller effect size of bevacizumab when combined with more effective chemotherapy, and statistical power [29].

COMBINATION THERAPY: TARGETING VEGF AND EGFR
Combining an antiangiogenic, single-target agent and a chemotherapeutic agent has resulted in proven activity across multiple tumor types; however, the future of cancer treatment may lie with the development of drugs or drug combinations that are directed against multiple tumor targets. Inhibition of multiple targets could be achieved with a single agent or with a combination of agents. In NSCLC, preclinical data in xenograft models have identified the VEGFR and EGFR pathways as rational therapeutic targets; inhibition of tumor growth was most pronounced with the combination of bevacizumab and the anti-EGFR TKI erlotinib (Tarceva®; Genentech, Inc., South San Francisco, CA) than with either agent alone [30]. The anti-EGFR monoclonal antibody cetuximab (Erbitux®; Merck Serono, Darmstadt, Germany) has shown promising antitumor activity in NSCLC and was studied in combination with bevacizumab plus chemotherapy in a phase II Southwest Oncology Group (SWOG) trial. The treatment combination was tolerable and evidence of antitumor activity was reported in a presentation at the annual meeting of the American Society for Clinical Oncology (ASCO) in 2009 [31].

A phase I/II study of erlotinib plus bevacizumab en-
rolled patients with pretreated nonsquamous, advanced NSCLC. The median OS time was 12.6 months and the PFS duration was 6.2 months [32]. Results from another phase II study in pretreated patients again supported further study with this treatment combination; bevacizumab plus erlotinib achieved activity comparable with that of bevacizumab plus chemotherapy (median OS time, 13.7 months for bevacizumab plus erlotinib versus 12.6 months for bevacizumab plus chemotherapy) [33]. Consequently, this combination was studied in the phase III BeTa Lung trial in pretreated patients with advanced NSCLC. Unfortunately, the primary endpoint of a longer OS time than with erlotinib alone was not met (median OS time, 9.3 months versus 9.2 months; \( p = .75 \); hazard ratio [HR], 0.97) [34].

More recently, other trials have been presented, including the phase III ATLAS trial (investigating bevacizumab and erlotinib versus bevacizumab plus placebo, as maintenance therapy following first-line treatment) [35]. That study was stopped early on the recommendation of an independent data safety monitoring committee after a preplanned interim analysis that showed the combination led to a significantly longer PFS interval than with bevacizumab plus placebo.

**MULTITARGETED AGENTS**

Efforts to identify drugs that inhibit key pathways involved in the pathogenesis of cancer have led to the development of multitargeted agents. Small-molecule TKIs that inhibit receptors such as VEGFR, PDGFR, Raf, and KIT simultaneously may offer advantages over agents with single targets, and therefore a higher likelihood of single-agent activity. In addition, because multitargeted TKIs are often available orally, they may be more convenient for patients. Conversely, a potential disadvantage is the potential for toxicity resulting from off-target kinase inhibition, and the additive toxicity that may be particularly relevant when the agents are combined with chemotherapy.

Several multtargeted, angiogenic agents have been studied in clinical trials. Most of these agents inhibit VEGFR, and some also inhibit PDGFR, Raf, and EGFR (Table 2). Clinical experience with these compounds is described below. Those currently being investigated in phase III trials are summarized in Table 3.

| Agent   | VEGFR-1 | VEGFR-2 | VEGFR-3 | PDGFR | EGFR | Other targets |
|---------|---------|---------|---------|-------|------|---------------|
| Vandetanib | ●●     | ●      |         |      |      | RET           |
| Sunitinib | ●●●●   | ●      | ●      | ●    |      | KIT, FLT3, RET |
| Axitinib | ●●●●   | ●      | ●      | ●    |      | KIT, RA, FLT3  |
| Sorafenib | ●●     | ●      | ●      | ●    |      | KIT, RET      |
| Vatalanib | ●●●     | ●      | ●      | ●    |      | KIT           |
| Cediranib | ●●●●   | ●      | ●      | ●    |      | KIT           |
| Motesanib | ●●●     | ●      | ●      | ●    |      | KIT           |
| Pazopanib | ●●     | ●      | ●      | ●    |      | KIT           |
| BIBF 1120 | ●●     | ●      | ●      | ●    |      | FGFR          |

Abbreviations: FGFR, fibroblast-like growth factor receptor; FLT3, FMS-like tyrosine kinase 3; KIT, stem cell factor receptor; RET, glial cell line-derived neurotrophic factor receptor; VEGFR, vascular endothelial growth factor receptor.

Vandetanib

Vandetanib (Zactima®, ZD6474; AstraZeneca Pharmaceuticals, Wilmington, DE) is a VEGFR and EGFR inhibitor, although the difference in the 50% inhibitory concentration for these two targets translates into more potent inhibition of VEGFR than EGFR at pharmacologically achievable doses. In a phase II trial, vandetanib in combination with carboplatin and paclitaxel led to a higher ORR and longer PFS time (primary endpoint) but no difference in OS when compared with vandetanib alone in chemotherapy-naïve patients with NSCLC [36]. Higher incidences of rash, diarrhea, asymptomatic QTc-related events, and hypertension were observed in the vandetanib arm. The study allowed enrollment of patients with central nervous system (CNS) metastases and all NSCLC histologies; patients who entered with CNS metastases or squamous histology did not experience intracranial bleeding or hemoptysis of grade ≥2 [36]. The vandetanib-alone arm was stopped early after an interim analysis met the criterion for discontinuation. Vandetanib plus docetaxel was shown to be superior to docetaxel alone in pretreated patients with advanced NSCLC, and vandetanib led to a significantly longer PFS time than with gefitinib, again in a second-line setting [37, 38]. Subsequently, an extensive phase III program has been conducted: ZODIAC (vandetanib plus docetaxel versus
docetaxel alone) and ZEAL (vandetanib plus pemetrexed versus pemetrexed alone) are both placebo-controlled, double-blind, randomized studies evaluating the efficacy of vandetanib in second-line advanced NSCLC. Data presented at the 2009 ASCO Annual Meeting revealed acceptable safety profiles and significant improvements in response in both studies versus chemotherapy alone. Similarly, improvements in the primary endpoint (PFS versus chemotherapy alone) were reported but statistical significance was reached only in ZODIAC (PFS for vandetanib plus docetaxel was 4 months versus 3.2 months for docetaxel alone; HR, 0.79; 95% confidence interval [CI], 0.70–0.90, \( p < .001 \)) [39, 40]. However, whether a 3-week improvement in PFS is clinically meaningful remains to be determined. ZEST is a phase III head-to-head comparison of vandetanib versus erlotinib. Again, based on data reported at the 2009 ASCO Annual Meeting, the primary endpoint of PFS was not met (vandetanib, 11.3 weeks versus erlotinib, 8.9 weeks; HR, 0.98; 95% CI, 0.87–1.10; \( p = .721 \)) [41]. Finally, ZEPHYR is a randomized, double-blind phase III study of vandetanib plus best supportive care versus best supportive care alone in patients with advanced NSCLC after failure of prior treatment with an anti-EGFR TKI, and results are expected in 2010. Based on these data, the role of vandetanib in NSCLC remains somewhat uncertain; the initial results are frankly somewhat disappointing.

### Sunitinib

Sunitinib (Sutent®, SU11248; Pfizer Inc., New York) is an inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFRs, KIT, FLT3, RET, and CSF-1R, and is approved multinationally for the treatment of advanced renal cell carcinoma (RCC) and imatinib-resistant or imatinib-intolerant gastrointestinal stromal tumor. The antitumor activity of sunitinib in NSCLC is supported by preclinical data derived from in vivo models. Combination treatment with sunitinib plus docetaxel, pemetrexed, gemcitabine, or platinum agents resulted in significantly greater tumor growth inhibition than with sunitinib alone [42]. In a phase II trial, in which sunitinib was administered on a continuous daily dosing (CDD) schedule in patients with previously treated NSCLC, the median PFS time was 11.9 weeks (95% CI, 8.6–14.1 weeks), the median OS time was 37.1 weeks (95% CI, 24.2–52.5), and treatment was generally well tolerated; most adverse events were grade 1 or 2 [43]. An earlier pa-

### Table 3. Active phase III trials of antiangiogenic multitargeted tyrosine kinase inhibitors in advanced NSCLC

| Agent              | Design                                                                 | Target enrollment (n) | Primary endpoint |
|--------------------|------------------------------------------------------------------------|-----------------------|------------------|
| Sunitinib (Sutent®) | Sunitinib + erlotinib versus erlotinib second/third line; NCT00457392 (SUN1087) | 956                   | OS               |
|                    | Sunitinib as maintenance therapy in nonprogressing patients following platinum-based chemotherapy; NCT00693992 (CALGB30607) | 156                   | PFS              |
| Sorafenib (Nexavar®) | Gemcitabine + cisplatin + sorafenib versus gemcitabine + cisplatin + placebo first-line; NCT00449033 (NEXUS) | 350                   | PFS              |
|                    | Sorafenib with or without placebo third/fourth line in patients with predominantly nonsquamous histology; NCT00863746 | 850                   | OS               |
| Vandetanib (Zactima®) | Vandetanib + BSC versus BSC after therapy with an EGFR TKI; NCT00404924 (ZEPHYR) | 930                   | OS               |
| Motesanib          | Motesanib + paclitaxel + carboplatin (MONET1); NCT00460317               | 1,400                 | OS               |
| BIBF 1120 (Vargatef®) | BIBF 1120 + pemetrexed versus placebo + pemetrexed second line in patients with nonsquamous histology; NCT00806819 (LUME Lung 2) | 1,302                 | PFS              |
|                    | BIBF 1120 + docetaxel versus placebo + docetaxel second line; NCT00805194 (LUME Lung 1) | 1,306                 | PFS              |

Information on ongoing phase III trials was obtained from http://www.clinicaltrials.gov (accessed December 2009) using the name of the TKI and “lung” as search criteria.

Abbreviations: BSC, best supportive care; CALGB, Cancer and Leukemia Group B; EGFR, epidermal growth factor receptor; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.
tient cohort in that trial received sunitinib, 50 mg/day, on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment); again, treatment appeared active with a median PFS duration of 12.0 weeks (95% CI, 10.0–16.1 weeks) and a median OS time of 23.4 weeks [44]. Sunitinib was well tolerated, with most adverse events being grade 1 or 2. Responses were also observed in a phase I study of sunitinib plus gemcitabine and cisplatin [45]. Ongoing trials of sunitinib in advanced, platinum-refractory NSCLC include SUN1058 and SUN1087 (Table 3). SUN1058 is a phase II trial investigating sunitinib (37.5 mg) plus erlotinib (150 mg) on a CDD schedule; patients are stratified based on smoking history and EGFR status. SUN1087 is a phase III trial investigating sunitinib (37.5 mg) plus erlotinib (150 mg) on a CDD schedule; patients are stratified based on smoking history and EGFR status. SUN1087 is a phase III trial investigating sunitinib (37.5 mg) plus erlotinib (150 mg), again on a CDD schedule, and employs the same stratification criteria in addition to stratification based on prior treatment with bevacizumab. By targeting EGFR as well as VEGFR and PDGFR, this combination may increase the potential for activity.

**Axitinib**

Axitinib (AG-013736; Pfizer Inc., New York) is a TKI with activity against all three VEGFRs (VEGFR-1, VEGFR-2, and VEGFR-3) at clinical doses and is currently being studied in multiple solid tumor settings [46]. In a phase II study of patients with advanced NSCLC treated with single-agent axitinib (in the first-line, second-line, or third-line setting), the median PFS interval was 4.9 months overall (95% CI, 3.6–7.0 months), and the median OS time of 14.6 months was greater than expected in such a mixed patient population [47]. Treatment was also well tolerated. Ongoing trials of this agent in nonsquamous NSCLC patients include the phase II AGILE 1030 trial (axitinib plus paclitaxel plus carboplatin versus bevacizumab plus paclitaxel plus carboplatin), the phase II AGILE 1039 trial (axitinib plus cisplatin and pemetrexed versus cisplatin and pemetrexed), and the phase II AGILE 1038 trial in squamous cell carcinoma (axitinib plus cisplatin and gemcitabine).

**Sorafenib**

Sorafenib (Nexavar®, BAY 43–9006; Bayer Pharmaceuticals Corporation, West Haven, CT) is a Raf and VEGFR inhibitor (VEGFR-2 and VEGFR-3) with activity against PDGFR and KIT. It is licensed in many countries for the treatment of advanced RCC and hepatocellular carcinoma [48]. In xenograft models, sorafenib plus vinorelbine, cisplatin, or gefitinib resulted in tumor growth delay at least comparable with that observed with each agent alone [49]. In the phase III ESCAPE trial (carboplatin plus paclitaxel, with and without sorafenib in first-line, advanced NSCLC), the primary endpoint of OS was not met and the study was terminated early as a result of the detrimental effect of sorafenib on patients with squamous cell carcinoma and the lack of effect in the population with nonsquamous cell car-

---

**Figure 1.** Pathways blocked by tyrosine kinase inhibitors and monoclonal antibodies.

Abbreviations: EGF, endothelial growth factor; EGFR, endothelial growth factor receptor; GRB2, growth factor receptor-bound protein-2; MAPK, mitogen-activated protein kinase; MEK, MAPK/extracellular signal–related kinase kinase; PI3K, phosphoinositide 3-kinase; PDGF, platelet-derived growth factor; PTEN, phosphatase and tensin homologue deleted on chromosome ten; SOS, son of sevenless; STAT, signal transducer and activator of transcription; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

---
cinoma. Further investigation of sorafenib in the third- or fourth-line treatment setting is currently under consideration [50]. Data from a phase II trial of heavily pretreated patients with advanced NSCLC revealed a statistically significant higher number of patients with stable disease at 2 months with sorafenib (sorafenib, 47% versus placebo, 19%; p = .01), and toxicities were manageable [51]. Single-agent sorafenib showed disease stabilization in 59% of 51 NSCLC patients in a phase II trial, with an OS time of 6.8 months and a median PFS time of 2.8 months [52].

**Vatalanib**

Vatalanib (PTK787; Novartis/Schering AG, Berlin, Germany) is a VEGFR, PDGFR, and KIT inhibitor that is currently being studied in phase II/III trials. Data from a phase II trial examining vatalanib monotherapy administered once or twice daily in previously treated patients with NSCLC have been reported [53]. Single-agent treatment appeared active, with a trend toward greater efficacy with twice-daily treatment (11% of evaluable patients had a partial response in this cohort). Additionally, treatment was well tolerated, with no apparent differences between once- and twice-daily dosing.

**Cediranib**

Cediranib (Recentin®, AZD2171; AstraZeneca Pharmaceuticals, Wilmington, DE) is a potent VEGFR-2 inhibitor that also inhibits VEGFR-1, VEGFR-3, and PDGFR [54]. Initial phase I data with cediranib (30 mg) in combination with cisplatin and gemcitabine was promising in patients with previously untreated NSCLC [55]. Toxicities, including hypertension, fatigue, and diarrhea, were manageable and predictable, with the maximum-tolerated dose not reached. Given that the 30-mg dose was better tolerated than the 45-mg dose in the phase I trial, the 30-mg dose of cediranib was selected for combination with carboplatin and paclitaxel in the first-line BR24 phase II/III study in patients with NSCLC. In early 2008, AstraZeneca reported that the study would not continue into phase III following the planned end of phase II efficacy and tolerability analyses. According to the study’s data safety monitoring committee, although evidence of clinical activity was observed, there appeared to be an imbalance in toxicity between the treatment and control arms, and therefore the study was considered not to have met the predefined criteria for continuation into phase III [56]. A retrospective analysis revealed a higher risk for weight loss, hypoalbuminemia, and grade 5 adverse events in patients receiving cediranib (30 mg) plus chemotherapy than in those receiving chemotherapy alone. However, despite these safety data, cediranib (30 mg) plus chemotherapy led to a higher response rate and longer PFS time than with chemotherapy alone [56]. Consequently, a reduced dose of cediranib (20 mg) plus carboplatin and paclitaxel will be investigated in a randomized trial in patients with a good performance status, no significant weight loss, and no hypoalbuminemia.

**Motesanib**

Motesanib (AMG 706; Amgen, Thousand Oaks, CA) is a VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, KIT, and RET inhibitor that is currently in clinical development in multiple tumor types, including NSCLC. Phase I data have shown that motesanib can be combined safely with paclitaxel plus carboplatin and/or panitumumab, an anti-EGFR monoclonal antibody, in patients with advanced NSCLC [57]. Treatment-related adverse events in that study were generally mild to moderate, with fatigue and hypertension being the most common grade 3 adverse events [57]. A phase III trial investigating motesanib (125 mg daily) in combination with paclitaxel and carboplatin was temporarily suspended in November 2008 because of a higher risk for hemoptysis in patients with squamous cell histology. These patients were discontinued and the study was re-started; patients with nonsquamous cell histology (approximately two thirds of the original study population) are continuing on treatment, and patients with this histology are continuing to be enrolled (Table 3).

**Pazopanib**

Pazopanib (GW786034; GlaxoSmithKline, Philadelphia) is a VEGFR, PDGFR, and KIT inhibitor currently in phase III development for advanced RCC and in phase II development in advanced NSCLC. Initial data from a phase II trial in early (stage I/II) NSCLC have been presented; 87% of patients (n = 20) had a reduction in tumor volume, and the tolerability profile in this setting was favorable [58]. Numerous phase II studies of pazopanib in patients with advanced NSCLC have either been completed or are ongoing, and data are keenly awaited. These include pazopanib as monotherapy, as well as combination studies with paclitaxel and pemetrexed. In addition, a phase II study of erlotinib plus pazopanib versus erlotinib plus placebo is planned [59]. Antitumor activity in the first-line setting was observed in patients with malignant pleural mesothelioma. A phase II study revealed a PFS duration of 5.9 months (95% CI, 3.1–8.4 months) and OS time of 14.4 months (95% CI, 7.2 to not achieved) [60].

**BIBF 1120**

BIBF 1120 (Vargatef™; Boehringer-Ingelheim, Ingelheim, Germany) is an oral indolinone derivative that inhibits VEGFR-2, FGFR, and PDGFR. Phase I data in
patients with advanced solid tumors established the phase II dose to be 200 mg twice daily and revealed that the observed toxicities at this dose were manageable. Adverse events judged to be related to treatment were most often gastrointestinal, and there were responses in patients (three of 23) with RCC and colorectal cancer [61]. Results from a phase II trial of BIBF 1120 involving patients with advanced NSCLC were reported at the 13th World Conference on Lung Cancer [62]. This double-blind multicenter trial included patients with an ECOG performance status score of 0–2 who had relapsed following the failure of first- or second-line chemotherapy. Again, adverse events were most often gastrointestinal; the most common grade 1–3 toxicities were vomiting, nausea, diarrhea, anorexia, and abdominal pain [62]. The median OS time was 264 days [63]. Phase III trials of BIBF 1120 in advanced NSCLC are under way—LUME Lung 1 and LUME Lung 2 (Table 3).

**Challenges Facing the Effective Treatment of NSCLC**

**Toxicity**

The TKIs described above all inhibit multiple receptors, therefore influencing multiple signaling pathways and their respective downstream signaling molecules. Consequently, the antitumor activity of these agents may be superior to that of agents with single targets; however, this must be balanced against the potential for additive toxicity. For example, inhibition of KIT has been associated with changes in skin and hair pigmentation, whereas inhibition of VEGFRs can lead to hypertension, hemorrhage, skin toxicity, fatigue, hand–foot syndrome, and hypothyroidism (also linked to inhibition of RET) [64–66]. Interestingly, some studies have suggested that hypertension may actually be a predictor of response in a variety of tumor types following treatment with multitargeted TKIs [67]. Furthermore, inhibition of PDGFR has been linked to cardiotoxicity (possibly as a result of the expression of PDGFR on cardiomyocytes), skin reactions, and edema.

Treatment with multitargeted TKIs may be associated with off-target kinase activities resulting in possibly unexpected side effects, for example, cardiac-related events [68]. Toxicities associated with the pharmacological action of antiangiogenic TKIs, so called “class-effect” toxicities, have also been reported, such as hypertension, hand–foot syndrome, and impaired wound healing [69, 70]. It is becoming increasingly clear that a comprehensive understanding of the spectrum of effects exerted by all anticancer agents, including multitargeted TKIs, is fundamental for understanding the efficacy and safety profiles of targeted agents. While most toxicities associated with TKIs are manageable, patients should continue to be monitored carefully for evidence of toxicity, particularly because prolonged periods of therapy may be required and side effects may impact treatment compliance.

**Combining Targeted Agents**

As discussed earlier, combining targeted agents is a valid strategy and is one that is being pursued in numerous trials (e.g., the SUN1087 trial). It is conceivable that such regimens may avoid the adverse effects commonly associated with chemotherapy, while providing comparable and possibly superior antitumor activity. The safety and efficacy data from the ATLAS study were recently presented. Although no unexpected safety signals were observed, grade 3 or 4 rash and diarrhea were more common in the erlotinib plus bevacizumab arm than in the bevacizumab plus placebo arm (10.4% versus 0.5% and 9.3% versus 0.8%, respectively) [35]. Based on the statistically significant longer median PFS time (the primary endpoint) of 4.8 months for the erlotinib plus bevacizumab arm, versus 3.7 months for the bevacizumab plus placebo arm (HR, 0.72; 95% CI, 0.59–0.88; p = .0012), that trial met its primary endpoint and was terminated early.

**Biomarkers of Response**

The effective use of VEGFR TKIs will depend on identifying patients who are most likely to benefit from therapy. A number of translational medicine biomarkers are being explored to identify predictors of response and/or toxicity based on a variety of parameters, such as tumor histology and pretreatment levels of angiogenic molecules such as VEGF and PDGF, levels of tumor-associated blood vessels (MVD), KRAS mutations, and levels of circulating endothelial cells (CECs). An in vitro profiling study reported at the ASCO–National Cancer Institute–European Organization for Research and Treatment of Cancer meeting demonstrated distinct patterns of protein secretion in response to certain treatment regimens [71]. Furthermore, evidence suggests a correlation between levels of some VEGF isoforms and survival in NSCLC patients [72, 73], with a particularly high correlation between levels of soluble VEGFR-2 and tumor shrinkage in response to pazopanib [74]. However, there are conflicting reports regarding the effectiveness of using pretreatment VEGF levels as a predictive biomarker, and it is possible that it is actually bioavailable, rather than circulating, VEGF that is the most effective predictor [75]. Similarly, high expression of PDGF-B and PDGFRα have been linked to poor outcome in tumor cells derived from patients with stage I–III NSCLC [76]. High MVD has been linked to poor survival and tumor progression in NSCLC patients, and it has a par-
ticularly strong correlation with the development of distant metastases [77]. In addition, it is hypothesized that treating patients with antiangiogenic agents may dissociate endothelial cells from the tumor vasculature, therefore increasing the number of CECs in patients’ blood. High levels of CECs may indicate that a patient is responding to treatment with an antiangiogenic agent, a theory with some preclinical support [78]. In summary, while efforts are under way to identify biomarkers predictive of response to antiangiogenic therapy, so far no single marker or set of markers seems ready for routine clinical use.

**SUMMARY**

Angiogenesis is a complex process that is essential for the growth of tumors. Initial clinical data have shown modest efficacy when single-target agents are combined with chemotherapy. Multitargeted antiangiogenic agents may provide advantages over agents with single targets; however, the use of one strategy over another will rely on optimizing the benefit–risk ratio of targeted agents, using clinical and translational medicine biomarker characteristics of individual patients. Further exploration of multitargeted angiogenesis inhibitors may offer additional clinical benefits and may pave the way toward the development of rational combinations of targeted agents for NSCLC. Because similar efficacy outcomes are being achieved with conventional chemotherapy agents, it is conceivable that chemotherapy regimens have reached a plateau in terms of efficacy, possibly because of the development of resistance [72, 79]. In addition, there is continuing debate over the efficacy and safety profiles of platinum- versus nonplatinum-based chemotherapy regimens, particularly when considering the potential toxicity concerns with platinum-based agents. As with all treatments, the advantages obtained in terms of activity must be weighed against the potential for greater treatment-related toxicity.

Ultimately, personalizing anticancer therapy through the use of biomarkers may improve the response to treatment. In addition, identifying the most effective treatment combinations, doses, and schedules may also help to improve response rates. It is conceivable that inhibiting angiogenesis may become a cornerstone of NSCLC treatment in the future.

**AUTHOR CONTRIBUTIONS**

**Conception/Design:** Giorgio Scagliotti, Ramaswamy Govindan

**Data analysis and interpretation:** Giorgio Scagliotti, Ramaswamy Govindan

**Manuscript writing:** Giorgio Scagliotti, Ramaswamy Govindan

**Final approval of manuscript:** Giorgio Scagliotti, Ramaswamy Govindan

The authors take full responsibility for the content of the paper. The role of the medical writer, Dr. Nicola Crofts, Ph.D., from ACUMED® (Thytherington, UK), was to assist the authors by collating and incorporating their feedback into each draft of the manuscript and preparing tables for the authors to review. Her contributions included copyediting/proofreading, editorial assistance, and production assistance. Dr. Nicola Crofts also liaised with ACUMED’s in-house studio to ensure that figures were prepared per the authors’ specifications. Medical writing support provided by Dr. Crofts was funded by Pfizer Inc.

**REFERENCES**

1. Figg WD, Folkman J. Angiogenesis: An Integrative Approach From Science to Medicine. New York: Springer, 2008.

2. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182–1186.

3. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401–410.

4. Herbst RS, Oun A, Sandler A. Angiogenesis and lung cancer: Prognostic and therapeutic implications. J Clin Oncol 2005;23:3243–3256.

5. Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 2005;7:452–464.

6. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999;18:5356–5362.

7. Döme B, Hendrix MJ, Paku S et al. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 2007;170:1–15.

8. Shikada Y, Yonemitsu Y, Koga T et al. Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res 2005;65:7241–7248.

9. Hasumi Y, Klosowska-Wardega A, Furushashi M et al. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 2007;121:2606–2614.

10. Erber R, Thurnher A, Katsen AD et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338–340.

11. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–676.

12. Hirschi KK, Rohovsky SA, Beck LH et al. Endothelial cells modulate the proliferation of mural cell precursors via platelet-derived growth factor-BB and heterotypic cell contact. Circ Res 1999;84:298–305.

13. Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev 2004;15:205–213.

14. Yu J, Ustach C, Kim HR. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 2003;36:49–59.

15. van Cuijksen H, Giaccone G, Hoekman K. Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. Int J Cancer 2005;117:883–888.

16. Douillard JY, Shepherd FA, Hirsh V et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744–752.

17. Koukourakis MI, Giatromanolaki A, Thorpe PE et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 2000;60:3088–3095.

18. O’Byrne KJ, Koukourakis MI, Giatromanolaki A et al. Vascular endothelia-
ial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000;82:1427–1432.

19 Kojima H, Shijubo N, Yamada G et al. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer 2005;104:1668–1677.

20 Takizawa H, Kondo K, Fujiy H et al. The balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small cell lung cancer. Br J Cancer 2006;95:75–79.

21 Hanrahan EO, Lin HY, Kim ES et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010;28:193–201.

22 Hanrahan EO, Ryan AJ, Mann H et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009;15:3600–3609.

23 Chen ZJ, Le HB, Zhang YK et al. MicrovesSEL density and expression of thrombospondin-1 in non-small cell lung cancer and their correlation with clinicopathological features. J Int Med 2009;37:551–556.

24 Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.

25 Ginsberg MS, Grewal RK, Heelan RT. Lung cancer. Radiol Clin North Am 2007;45:21–43.

26 Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 2008;26:3543–3551.

27 Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 2009;374:1432–1440.

28 Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542–2550.

29 Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAi1. J Clin Oncol 2009;27:1227–1234.

30 Sandler A, Herbst R. Combining targeted agents: Blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 2006;12:4421s–4425s.

31 Gandara D, Kim ES, Herbst RS et al. S0536: Carboplatin, paclitaxel, cetuximab and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced NSCLC: A SWOG phase II study. J Clin Oncol 2009;27:410s.

32 Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancer. J Clin Oncol 2005;23:2544–2555.

33 Herbst RS, O’Neill VJ, Fehrenbacher L et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol 2007;25:4743–4750.

34 Hainsworth J, Herbst R. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin) in combination with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy. J Thorac Oncol 2008;3(suppl 4):S263–S305.

35 Miller VA, O’Connor P, Soh C et al. A randomized, double-blind, placebo controlled, phase IIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic NSCLC. J Clin Oncol 2009;27:799s.

36 Heymach JV, Paz-Ares L, De Braud F et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008;26:5407–5415.

37 Heymach JV, Johnson BE, Prager D et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 2007;25:4270–4277.

38 Natale RB, Bodkin D, Govindan R et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized phase II study. J Clin Oncol 2009;27:2523–2529.

39 Herbst RS, Sun Y, Korale S et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZD1AC). J Clin Oncol 2009;27(18 suppl):Abstract CRA 8003.

40 De Boer R, Arrieta O, Gottfried M et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL). J Clin Oncol 2009;27(15 suppl):Abstract 8010.

41 Natale RB, Thongprasert S, Greco FA et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST). J Clin Oncol 2009;27(15 suppl):Abstract 8009.

42 Christensen JG, Hall C, Hollister BA. Antitumor efficacy of sunitinib malate in concurrent and sequential combinations with standard chemotherapeutic agents in non-small cell lung cancer (NSCLC) nonclinical models. Presented at the 99th Annual Meeting of the American Association for Cancer Research, San Diego, California, April 12–16, 2008.

43 Novello S, Scagliotti GV, Rosell R et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009;101:1543–1548.

44 Socinski MA, Novello S, Brahmer JR et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650–656.

45 Reck M, Frickhofen N, Cedres S et al. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study. Lung Cancer 2010 Feb 24 [Epub ahead of print].

46 Hu-Lowe DD, Zou HY, Grazzini ML et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14:7272–7283.

47 Schiller JH, Larson T, Ou SH et al. Efficacy and safety of axitinib in patients with advanced non-small cell lung cancer: Results from a phase II study. J Clin Oncol 2009;27:3836–3841.

48 Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–134.

49 Carter CA, Chen C, Brink C et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol 2007;59:183–195.

50 Scagliotti G, Von Pawel J, Reck M et al. Sorafenib plus carboplatin/paclitaxel in chemonaive patients with stage IIIb-IV NSCLC: Interim anal-
ysis results from the phase III, randomized, double-blind, placebo-controlled, ESCAPE (Evaluation of Sorafenib, Carboplatin and Paclitaxel Efficacy in NSCLC) trial. J Thorac Oncol 2008;3:S97–S98.

51 Schiller JH, Lee J, Hanna N et al. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens. J Clin Oncol 2008;26:4275.

52 Blumenschine GR Jr, Gatzemeier U, Fossella F et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27:4274–4280.

53 Gauler TC, Besse B, Gounant V et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1.250 mg as second-line monotherapy in patients (pts) with stage IIIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(18 suppl);Abstract 7541.

54 Wedge SR, Kendrew J, Hennesquin LF et al. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389–4400.

55 Goss G, Shepherd FA, Laurie S et al. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2009;45:782–788.

56 Goss GD, Arnold A, Shepherd FA et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study. J Clin Oncol 2010;28:49–55.

57 Blumenschine GJ, Sandler A, O’Rourke T et al. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of pts with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24:379s.

58 Altorki N, Guarino M, Lee P et al. Preoperative treatment with pazopanib (GW786034), a multitkiase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study. J Clin Oncol 2008;26(15 suppl);Abstract 7557.

59 www.ClinicalTrials.gov. Available at http://clinicaltrials.gov/2010, accessed December 2009.

60 Molina JR, Mandrekar SJ, Ziegler KLA et al. A phase II study of the VEGFR inhibitor pazopanib (P) in patients with newly diagnosed or relapsed malignant pleural mesothelioma (MPM): An NCCTG study [abstract PD4.1.2]. Presented at the 13th World Conference on Lung Cancer, San Francisco, California, July 31–August 4, 2009.

61 Mross K, Stefanic M, Gmeingh D et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16:311–319.

62 Reck M, Kaiser R, Eschbach C et al. A phase II double-blind study to investigate efficacy and safety of the triple angio kinase inhibitor BIBF 1120 in patients with relapsed advanced non-small cell lung cancer. World Conference on Lung Cancer, San Francisco, California, July 31–August 4, 2009.

63 Boehlerling Ingelheim. Boehlerling Ingelheim to Commence Phase III Study Investigating the Role of BBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Mutations [press release]. Available at http://www.bbovercorporation.com/newsroom/2009/08–03_bbw2992_release.html, accessed December 2009.

64 Tamaskar I, Bukowski R, Elson P et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 2008;19:265–268.

65 Wolter P, Schoffski P. Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management. Acta Oncol 2010;49:13–23.

66 Torino F, Corsello SM, Longo R et al. Hypothyroidism related to tyrosine kinase inhibitors: An emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009;6:219–228.

67 Rixe O, Dutcher JP, Motzer RJ et al. Association between diastolic blood pressure (DBP) ≥90 mmHg and efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving axitinib (AG-013736: AG). Ann Oncol 2008;19(suppl.8);Abstract S179.

68 Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010;106:21–34.

69 Izzedine H, Ederhy S, Goldwasser F et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;20:807–815.

70 Myaskowski PL, Halpern AC. Skin reactions to the new biologic anticancer drugs. Curr Opin Support Palliat Care 2009;3:294–299.

71 Byers LA, Tran HT, Tumula PK et al. Use of cytokine and angiogenic factor (CAF) profiling of non-small cell lung cancer cell lines to identify secreted proteins associated with response to chemotherapy and targeted agents [abstract 65]. Presented at the ASCO-NCI-EORTC Molecular Markers Meeting, Hollywood, Florida, October 30–November 1, 2008.

72 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: NSCLC v. 2.2009. Available at http://www.nccn.org/professionals/physician_gls/PDF/nscl pdf 2009, accessed December 2009.

73 Heist RS, Zhai R, Liu G et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008;26:856–862.

74 Nikolianakos P, Altorki N, Guarino M et al. Analyses of plasma cytokine/angiogenic factors (C/AFs) profile during preoperative treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer. J Clin Oncol 2008;26:2008 (15 suppl);Abstract 7568.

75 Davidson AM, Ng CY, Zhang Y et al. Careful decay receptor titering is required to inhibit tumor angiogenesis while avoiding adversely altering VEGF bioavailability. Mol Ther 2005;11:300–310.

76 Donnem T, Al-Saad S, Al-Shibli K et al. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol 2008;3:963–970.

77 Fontanini G, Bigini D, Vignati S et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 1995;177:57–63.

78 Norden-Zfoni A, Manola J, Desai J et al. Levels of circulating endothelial cells and monocytes as pharmacodynamic markers of SU11248 activity in patients with metastatic imatinib-resistant GIST. Proc Am Soc Clin Oncol 2005;23(16 suppl);Abstract 9036.

79 Keedy VL, Sandler AB. Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci 2007;98:1825–1830.